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Abstract
Background: Whether there is a temporal relationship between psychological problems and clinical outcomes
in patients with diseases of the digestive tract has not been widely researched. Thus, our aims were 1) To observe
and compare prospectively clinical outcomes in relation to psychological co-morbidity in patients with
inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and chronic hepatitis C (HCV) and, 2) To test
the hypothesis that patients with psychological co-morbidities are less likely to have a satisfactory response to
standard treatment at 12 months.
Methods: Overall, 139 patients were enrolled in this observational cohort prospective study. Over the ensuing
year, physical and psychological measures were made at baseline and after 12 months (HADS, SCL90, SF-12 and
disease activity measures). A logistic regression was conducted to observe any relationship between baseline
characteristics and patients' clinical outcomes after 12 months.
Results: Overall, there was no relationship between psychological status and quality of life at baseline and relapse
at 12 months (p > 0.05). However, patients with inactive disease at baseline were at lower risk of relapse after
12 months (OR = 0.046, CI: 0.012–0.178). No significant relationship was found between psychological problems
such as depression/anxiety and a total number of relapses in the IBD group. However, interestingly, patients with
an active disease at baseline tended to have a greater number of relapses (OR = 3.07, CI: 1.650–5.738) and CD
participants were found at lower risk of relapse than UC participants (OR = 0.382, CI: 0.198–0.736).
Conclusion: In contrast to previous investigations, this study suggests that there is no temporal relationship
between psychological problems at baseline and clinical outcomes over time. Longer and larger prospective
studies are needed to better understand this result.
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Diseases of the digestive tract frequently coexist with psy-
chological disorders [1-3]. However, a temporal relation-
ship between psychological problems and clinical
outcomes in patients with gastroenterological disorders
has not been widely researched.
Inflammatory bowel disease (IBD) is a generic term used
to describe a group of chronic relapsing inflammatory dis-
orders of the gastrointestinal tract, of which Crohn's dis-
ease (CD) and ulcerative colitis (UC) are the most
common. The prevalence of IBD ranges from 37 to 246
cases per 100,000 persons for UC and from 26 to 199
cases per 100,000 persons for CD depending on the
region of the world [4], with a peak incidence around 20
years of age. The aetiology of IBD is unknown. Nonethe-
less, genetic, immune and environmental factors have all
been implicated in its causation [5,6]. Some researchers
have also controversially proposed that IBD may be partly
a psychosomatic disease [7-11]. However, the editors of
major texts in gastroenterology claim that psychological
factors are a result, rather than a cause of IBD, and that
they do not contribute to the aetiology [12,13]. Although
the possible psychosomatic origin of IBD is disputed,
many studies report that stressful life events do exacerbate
the disease [14-17].
Consistent with these observations in IBD, in the majority
of other gastrointestinal problems, depression and anxi-
ety are considered to be a consequence of chronic somatic
disease or treatment side-effects (e.g. interferon-ribavirin
and depression) rather than causal factors [18]. The excep-
tion may be functional gastrointestinal disorders which
some authors believe have psychological factors implied
in their causation [19]. However, even in this group of
conditions there has been little prospective research con-
ducted on the relationship between psychological status
at baseline and clinical outcomes over time.
In patients with irritable bowel syndrome (IBS), which is
the most well recognised of the functional gastrointestinal
disorders, bowel habits are altered (constipation and/or
diarrhoea) with absence of any apparent mechanical, bio-
chemical and inflammatory changes in the gastrointesti-
nal tract [20]. Surprisingly, a prospective study of 400 IBS
participants has found that anxiety, depression and stress
are all predictors of better health outcomes over a 12
month period [21]. Whereas another 5-year follow-up
study with 43 participants has indicated that anxiety but
not depression may have a negative impact on the clinical
outcomes in IBS [22]. In contrast, a systematic review
including 14 observational longitudinal studies has docu-
mented that both anxiety (two studies including the one
by Fowlie et al. 1992) and depression (one study) at base-
line predicted worse clinical outcomes after a period of
observation [23]. These somewhat conflicting results
make it impossible to confidently conclude whether psy-
chological status affects clinical outcomes in patients with
IBS and whether the effects are positive or negative.
Prospective studies on the relationship between psycho-
logical status and clinical outcomes in chronic hepatitis C
(HCV), a chronic infectious disorder that carries a mortal-
ity risk from cirrhosis, end-stage liver disease and liver
cancer [24], and IBD are even more of a rarity. In fact,
searching for prospective studies on depression in HCV,
among the 49 results, the only papers found all relate to
depression as a side-effect of interferon therapy. With
regard to IBD, among 18 identified studies, the majority
relate to stress and psychotherapy, with only three pro-
spective investigations into the relationship between
depression/anxiety and clinical outcomes [25-27]. The
two largest of these three studies have demonstrated a link
between psychological problems and poorer clinical out-
comes [26,27], whereas a study with a small sample (n =
32) but with the longest follow-up period did not confirm
this finding [25].
Moreover, the majority of controlled studies in this area
suffer from methodological flaws such as comparisons
with inadequately matched controls. In fact, among the
three available studies on the relationship between
depression and clinical outcomes in IBD, none is control-
led [25-27]. The present study aims to avoid this limita-
tion.
The innovative aspects of the present study are therefore:
the groups under investigation; its prospective design,
comparisons with appropriate disease controls and; most
importantly, its focus on the relation between anxiety,
depression and clinical outcomes. Furthermore, as the
temporal differences in psychological profiles, the quality
of life and disease activity between patients with inflam-
matory bowel disease, irritable bowel syndrome, and hep-
atitis C have not been previously examined, discovering
their character and directions might contribute to under-
standing the nature of problems affecting these patients
and consequently, to improved medical care. The follow-
ing hypothesis is investigated in this study:
- Patients with psychological co-morbidities are less likely
to have better clinical outcomes (remission) at 12
months.
Materials and methods
Participants and recruitment
Patients with clinically diagnosed IBD, IBS and HCV were
recruited to this observational cohort prospective study
between November 2005 and June 2006 through the Out-
patient Clinic at the Department of Gastroenterology andPage 2 of 9
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each had sufficient knowledge of English to understand
and answer the questionnaires. Gastroenterology clinic
consultants individually invited eligible patients to partic-
ipate. After obtaining patients' consent, consultants
passed patients' contact details to the first author who
then made contact and provided written information
regarding the study. The study was described to potential
participants and each participant was provided with a
consent form, questionnaires and a reply paid envelope.
Through the year of the study, participants were adminis-
tered a number of screening instruments: IBS and HCV
patients on two occasions (baseline and 12 months) and
IBD patients on five occasions (baseline, 3, 6, 9 and 12
months). At each of these time points, participants were
asked to complete a survey comprising a measure of anxi-
ety and depression; a measure of a broad psychological
profile; a measure of quality of life; and a measure of dis-
ease activity (or in the case of patients with HCV, a blood
test to assess for ongoing active viral replication). Partici-
pants were given a choice to complete the questionnaires
at hospital or at home.
Measurements
Anxiety and depression screening
Screening for anxiety and depression was conducted with
the Hospital Anxiety and Depression Scale (HADS). The
HADS contains 14 questions graded on a 4-point Likert
scale (0–3), with subscales of anxiety (seven items) and
depression (seven items), with a sum score ranging from
0 to 21. A cut-off value for clinical caseness is 7. Scores
between 8 and 10 are interpreted as possible cases, and ≥
11 as certain cases.
Psychological profiles
Participants' broad psychological profiles were assessed
by the SCL-90-R Symptom Checklist (SCL-90). This is a
90-item self-report instrument. The SCL-90 contains 9
subscales: Somatization, Obsessive-Compulsive, Depres-
sion, Anxiety, Hostility, Phobic Anxiety, Paranoid Idea-
tion, and Psychoticism. It also comprises three global
indices: Global Severity Index (GSI), Positive Symptom
Distress Index, and Positive Symptom Total [28]. There
are no specified cut-off values for this scale; however, case-
ness can be identified when the GSI score ≥ 63 (after the
transformation into the T score) or when any two primary
dimension scores are ≥ 63.
Quality of life
Screening for quality of life was performed with the use of
the Short Form 12 Health Survey (SF-12). The SF-12 con-
tains two subscales: the Mental Component Summary
(MCS) and the Physical Component Summary (PCS)
[29]. Scores for each subscale range between 0 and 100,
with increasing values indicating better health.
Disease activity and the definition of remission
Disease activity in IBD participants was assessed with the
Crohn's Disease Activity Index (CDAI) [30] or the Simple
Clinical Colitis Activity Index (SCCAI) [31] as appropri-
ate. A CDAI score ≤ 150 was considered remission in CD
and a SCCAI score of ≤ 2 was considered remission in UC;
thus CDAI scores of more than 150, and SCCAI scores > 2
were considered a relapse (active disease).
Disease activity in IBS patients was measured by two ques-
tions added into the general health survey: "Have you got
satisfactory control of your IBS symptoms over the last 3
months?" and "Are you now feeling better or worse when
compared to your last visit in the clinic?" Answering "yes"
and "better" to these questions was considered remission
in IBS. Other responses were considered a relapse (active
disease). These questions were used as IBS is a symptom-
based diagnosis, according to a patient report (the Rome
criteria). The three month time frame was selected as it
corresponds to published diagnostic measures [32]. Given
the symptom based expression of this disease, "satisfac-
tory control" as judged by the patient is arguably the most
valid single tool to assess relapse/remission status.
Disease activity in HCV (or, more precisely, active viral
replication) was measured by RT-PCR HCVRNA. RT-PCR
HCVRNA "Not detected" was considered remission of
HCV and "Detected" was considered a relapse (active dis-
ease).
The primary outcome measure in this study was remission
(inactive disease) as compared to relapse (active disease).
Standard medical treatment
Standard medical treatment included regular visits at the
clinic and the medication prescribed by the treating doc-
tor. No interventions were made. Further appointments
were not "regular" they were at discretion of the referring
doctor according to medical needs.
Ethical considerations
The study was approved by the Royal Adelaide Hospital
Research Ethics Committee. Participants were aware that
their care did not in any way depend on participation or
non-participation in the study. Each participant provided
written informed consent. The work was performed in
accordance with the principles of the 1983 Declaration of
Helsinki [33].
Statistical analysis
Powering the study to detect differences of more than
15% for the primary outcome variables with an alpha-
level of 0.05 and a beta-level of 0.86 a sample size of at
least 150 patients (50 in each patient group) was esti-
mated to be acceptable for this trial. Estimates were basedPage 3 of 9
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[26,27,34,35]. However, due to the lack of good quality
data in this area and absence of local data, this power cal-
culation was an educated guess and was regarded as an
indication only. In terms of recruitment, the expected
sample sizes were larger and it was planned to recruit 50
to 125 participants to the IBD group and 50 to 75 partici-
pants to each of the IBS and HCV groups. The intended
total sample (for IBD, IBS and HCV) was 150 – 275
patients.
A logistic regression with a binomial dependent variable
was conducted to observe a relationship between baseline
characteristics (Point 0) and patients' clinical outcomes
after 12 months (Point 4). The analysis was adjusted for
disease activity at baseline, sex, years since diagnosis and
age. In order to obtain more parsimonious results, after
building a general model for all the psychological varia-
bles versus relapse, data were explored as part of a model
with significant and demographics variables only. A Pois-
son regression analysis was conducted to observe whether
there was any relationship between baseline characteris-
tics and the total number of time points at which the IBD
group had active disease (were in relapse). Demographic
comparisons and comparisons between CD and UC par-
ticipants were included into the analysis.
Results
Overall, 139 patients were enrolled in this observational
cohort prospective study. After 12 months of the study, 13
(9.3%) participants withdrew. These included seven
patients with IBD, five patients with HCV and one patient
with IBS. Five participants were not contactable, three
were too sick to be able to participate (Cancer, Alzheimer
disease, serious relapse of IBD). Another three partici-
pants did not send back the questionnaires despite the
reminders. One IBS patient's diagnosis was changed to
Coeliac disease and one person did not wish to be
involved anymore. Thus, 126 (90.7%) participants com-
pleted the study. Only incomplete data were available for
two IBS patients. The analysis was, therefore, restricted to
124 participants (59 IBD patients [32 CD and 27 UC], 36
HCV and 29 IBS). Unfortunately, the study was under-
powered for the HCV and IBS group, as the estimated
sample size of at least 50 patients in each disease group
was not achieved in these two groups.
Overall, 33 IBD participants received treatment with
immunosuppressant and eight patients received pred-
nisolone. Five HCV patients received antiviral treatment
(Interferon-Ribavirin). Overall, 17 patients received anti-
depressants (6 IBD, 6 HCV and 5 IBS). Moreover, in the
HCV group, 10 people did not receive any medication. In
the IBS group, three people did not receive any medica-
tion and in the IBD group, two people did not receive any
medication.
Baseline characteristics and patients' clinical outcomes 
after 12 months
Overall, there were 77 (62%) female and 47 (38%) male
participants. Groups did not differ in the distribution of
sex. The mean age was 50 years (SD = 13), with no differ-
ence between groups. The duration of disease was 12 years
(SD = 9), with IBD participants having significantly longer
disease duration than HCV participants (15 (SD = 10) vs.
8 (SD = 5) years, p = 0.002). Overall, 55 participants
(44%) completed secondary education and 38 (30%)
completed tertiary education.
Descriptive statistics for the relapse/remission status in all
three groups at baseline and after 12 months are pre-
sented in Table 1. Both, at baseline and after 12 months,
44% (CI: 35.3–52.7) of participants were in relapse. The
median baseline CDAI score was 34 with a range of 0–
319. The median baseline SCCAI score was 2.5 with a
range of 0–10. There was no difference in the number of
participants with active disease at baseline and after 12
months in any of the groups (Table 1).
At baseline, 40% participants were anxious and 17%
depressed (see Tables 2 and 3). At 12 months, 37% of par-
ticipants were anxious and 13% depressed. There was no
significant change over time either in the anxiety caseness
(χ2 (1) = 1.05 p = 0.305) or in the depression caseness (χ2
(1) = 1.11 p = 0.291) for the total cohort. There was also
no group differences in either anxiety or depression case-
ness over time (See Tables 2 and 3). There were no signif-
icant differences between groups in the risk of relapse after
Table 2: Anxiety cases (HADS Anxiety > 7) at baseline and after 
12 months
Baseline At 12 months
Percentage (CI)
HCV (n = 36) 44(27.8–60.2) 33(17.6–48.4)
IBD (n = 59) 39(26.6–51.4) 34(21.9–46.1)
IBS (n = 29) 52(33.8–70.2) 48(29.8–66.2)
Total (n = 124) 40(31.4–48.6) 37(28.5–45.5)
Table 1: The distribution of active disease in HCV, IBD and IBS 
at baseline and after 12 months
Baseline At 12 months
Percentage (CI)
HCV (n = 36) 53(36.7–69.3) 36(20.3–51.7)
IBD (n = 59) 32(20.1–43.9) 39(26.6–51.4)
IBS (n = 29) 59(41.1–76.9) 65(47.6–82.4)
Total (n = 124) 44(35.3–52.7) 44(35.3–52.7)Page 4 of 9
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sion (Table 4).
As the model did not provide a direct comparison
between IBD and IBS patients in their risk of being in
relapse after 12 months, an additional contrast was con-
ducted. The groups were found not to differ with this
respect (OR = 0.319, CI: 0.072–1.424, p = 0.134).
In the whole cohort, patients with lower scores on the
SCL90 Paranoid Ideation subscale were at lower risk of
relapse after 12 months than those with higher scores (OR
= 0.906, CI: 0.834–0.985 in Table 4). However, no other
psychological variable showed any significant relation-
ship to the risk of being in relapse after 12 months. Inter-
estingly, those patients with inactive disease at baseline
were at significantly lower risk of being in relapse after 12
months (OR = 0.046, CI: 0.012–0.178). Moreover, older
participants were at greater risk of relapse after 12 months
than younger participants (OR = 1.072, CI: 1.018–1.129).
When the analysis was rerun with significant and demo-
graphic variables only, those patients with an inactive dis-
ease at baseline remained at lower risk of active disease
after 12 months (OR = 0.089, CI: 0.035–0.229), whilst the
significance for the SCL90 Paranoid Ideation subscale dis-
appeared (OR = 0.964, CI: 0.923–1.007, p = 0.099).
Again, the p value of 0.025 indicated that older partici-
pants were at greater risk of relapse after 12 months; how-
ever, the confidence intervals show this difference is
barely significant (OR = 1.043, CI: 1.005–1.082).
As the main model comprised a large number of variables
potentially overlapping (with many of them being psy-
chological in nature), we subsequently created three
smaller models to ensure we were not "over fitting" the
data. In each of these three models, we controlled for age,
sex, years since diagnosis and disease activity at baseline.
In the first model, we examined anxiety, depression
(HADS) and quality of life (SF-12). In the second model,
we examined all the SCL90 variables. In the third model,
we examined only whether a participant met caseness
(score > 7) for either anxiety or depression. In all the three
models, the variable showing a significant difference was
disease activity at baseline. Patients with an inactive dis-
ease at baseline were at lower risk of active disease after 12
months (OR = 0.104, CI: 0.040–0.272). There was no
Table 4: Interactions between all psychological, demographic and disease activity variables and the risk of relapse at 12 months in IBD, 
IBS and HCV patients
Adjusted OR1 95% CI p
Disease status at baseline 0.046 0.012–0.178 <0.001
Female vs. male 0.537 0.142–2.033 0.360
Age 1.072 1.018–1.129 0.009
Years since Diagnosis 0.991 0.931–1.055 0.769
HADS Anxiety 1.216 0.929–1.591 0.154
HADS Depression 1.110 0.869–1.419 0.403
SF12 Mental 1.009 0.936–1.088 0.809
SF12 Physical 1.015 0.951–1.083 0.653
SCL90 Somatisation 1.045 0.956–1.142 0.330
SCL90 Obsessive-compulsive 0.950 0.861–1.048 0.305
SCL90 Interpersonal sensitivity 1.070 0.965–1.185 0.199
SCL90 Depression 1.014 0.882–1.166 0.843
SCL90 Anxiety 0.979 0.874–1.097 0.718
SCL90 Hostility 1.009 0.930–1.095 0.825
SCL90 Phobic anxiety 1.047 0.961–1.140 0.292
SCL90 Paranoid ideation 0.906 0.834–0.985 0.020
SCL90 Psychoticism 1.080 0.973–1.198 0.147
SCL90 GSI 1.025 0.818–1.283 0.832
SCL90 PST 0.936 0.731–1.199 0.602
SCL90 PSDI 0.887 0.782–1.005 0.060
IBS vs. HCV 1.576 0.371–6.705 0.538
IBD vs. HCV 4.940 0.881–27.689 0.069
1 The analysis was adjusted for disease activity at baseline, sex, years since diagnosis and age
Table 3: Depression cases (HADS Depression > 7) at baseline 
and after 12 months
Baseline At 12 months
Percentage (CI)
HCV (n = 36) 33(17.6–48.4) 11(0.8–21.2)
IBD (n = 59) 12(3.7–20.3) 15(5.9–24.1)
IBS (n = 29) 10(0-20.9) 10(0-20.9)
Total (n = 124) 17(10.4–23.6) 13(7.1–18.9)Page 5 of 9
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12 months. However, patients with lower scores on the
SCL90 Paranoid Ideation subscale were at lower risk of
relapse after 12 months than those with higher scores (OR
= 0.900, CI: 0.831–0.974). These findings confirm the
negative observations from the above large model and
lend support to the conclusion that there is, in fact, no
relationship between psychological variables and clinical
outcomes in this group of patients.
Interactions between psychological variables and a total 
number of relapses in IBD
A total number of relapses in IBD patients at five time
points of the 12-month study period are presented in
Table 5. No significant relationship was found between
psychological problems such as depression/anxiety and
the total number of relapses in the IBD group (Table 6).
However, interestingly, CD participants (n = 32) were
found to have a lower risk of relapse than UC participants
(n = 27) (OR = 0.383, CI: 0.198–0.736). Moreover,
patients with an active disease at baseline tended to have
a greater number of relapses (p < 0.0001) (OR = 3.07, CI:
1.650–5.738). We subsequently created two smaller mod-
els to confirm these findings. We controlled for age, sex,
years since diagnosis, IBD subtype and disease activity at
baseline. In the first model, we examined anxiety, depres-
sion (HADS) and quality of life (SF-12). In the second
model, we explored SCL90 subscales. The only significant
differences in the total number of relapses were again
between CD and UC patients (Model 1: OR = 0.392, CI:
0.223–0.690; Model 2: OR = 0.426, CI: 0.241–0.752) and
between those with active versus inactive disease at base-
line (Model 1: OR = 2.769, CI: 1.660–4.619; Model 2: OR
= 3.501, CI: 2.118–5.786).
Discussion
There have been few studies to prospectively evaluate the
relationship between depression and anxiety and patients'
clinical outcomes. While studies conducted with other
disease groups [36-38] have shown a link between psy-
chological status and clinical outcomes, this investigation
has not confirmed this observation for a cohort of patients
with chronic gastrointestinal diseases.
Of note, this observational cohort study was only the
fourth prospective, but the first controlled, investigation
into the relationship between psychological status and
clinical outcomes in patients with inflammatory bowel
disease [25-27]. In contrast to previous observations
[26,27], here we found that depression/anxiety at baseline
was not associated with a total number of relapses after a
period of time. Nevertheless, our results are consistent
with other findings [25]. Other investigators [26], how-
Table 5: Total number of relapses in the IBD group (n = 59) over 
the 12-month period
0 1 2 3 4 5
Frequency (%) 22(37) 11(19) 7(12) 3(5) 5(8) 11(19)
Table 6: Interactions between psychological variables and a total number of relapses in the IBD group (nCD = 32 and nUC = 27)1
Adjusted OR1 95% CI p
Disease status at baseline 3.07 1.650–5.738 <0.0001
Female vs. male 1.19 0.677–2.117 0.535
Age 0.993 0.972–1.013 0.472
Years since Diagnosis 0.991 0.961–1.021 0.536
CD vs. UC 0.382 0.198–0.736 0.004
HADS Anxiety 0.967 0.841–1.111 0.632
HADS Depression 1.057 0.919–1.215 0.438
SF12 Mental 1.020 0.973–1.070 0.409
SF12 Physical 0.984 0.950–1.019 0.357
SCL90 Somatisation 1.012 0.972–1.055 0.554
SCL90 Obsessive-compulsive 0.993 0.942–1.047 0.800
SCL90 Interpersonal sensitivity 1.022 0.976–1.069 0.358
SCL90 Depression 1.003 0.928–1.085 0.931
SCL90 Anxiety 1.040 0.989–1.092 0.124
SCL90 Hostility 1.030 0.982–1.081 0.220
SCL90 Phobic anxiety 0.999 0.964–1.037 0.976
SCL90 Paranoid ideation 0.996 0.961–1.033 0.848
SCL90 Psychoticism 0.989 0.936–1.044 0.689
SCL90 GSI 0.999 0.909–1.098 0.983
SCL90 PST 0.962 0.832–1.111 0.596
SCL90 PSDI 0.979 0.936–1.025 0.375
1 The analysis controlled for disease activity at baseline, sex, age, years since diagnosis and subtype of IBD (CD or UC)Page 6 of 9
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accurate comparisons cannot be made. Interestingly,
though, these researchers [26] have observed that psycho-
logical status adversely affected clinical outcomes only in
patients with Crohn's disease, but not in those with ulcer-
ative colitis.
The study by Mittermaier et al. [27], lasted for 18 months
and thus, was six months longer than the present investi-
gation. This might, in part, explain why the researchers
found a positive relationship between depression at base-
line and poorer clinical outcomes after 18 months. On the
other hand, North et al. [25] observed their cohort of IBD
patients for longer (two years), yet they did not observe a
link between depression and worse clinical outcomes. The
latter study, however, included only 32 participants. It is
probable that larger and longer lasting studies could help
understand these findings.
Sample size in the present study is comparable to that of
Mittermaier et al. [27] (n = 59 vs. n = 60, respectively). As
mentioned above their observations lasted 18 months,
however, of more relevance, they reported a far greater
baseline prevalence of depression – 28% as compared to
our cohort's prevalence of only 12% [27]. This indicates
significant differences between their cohort and ours,
which are likely to have contributed significantly to our
different findings. Interestingly, Mittermaier's patients
were all in remission at baseline [27] and thus, should
have had a low rate of psychological problems, while in
the current study although only 61% of IBD patients were
in remission at recruitment our cohort had a markedly
lower rate of depression. To gather precisely comparable
data further studies which recruit only IBD patients in
remission would be required. However, allowing for this
discrepancy in cohorts, when our analysis controlled for
disease activity at baseline it did not appear to impact the
results.
The largest limitation of the study by Mittermaier et al.
[27] is the use of the Beck Depression Inventory (BDI),
which is not as precise as the HADS in screening for
depression and anxiety in IBD. In fact, five items in the
BDI overlap with somatic symptoms of IBD: appetite,
weight loss (two questions), general fatigue and worries
about health. This may mean they over-diagnosed depres-
sion [27]. North et al. [25], on the other hand, avoided
this flaw by removing these overlapping items from their
version of the BDI. Thus, even though they had a smaller
sample size, they applied greater rigour and had a greater
length of observation [25]. Their data, adds weight to our
findings, as they [25] also found no link between psycho-
logical status and clinical outcomes in patients with IBD.
As regards the HCV group, no similar studies have been
performed and thus, no comparisons are possible. With
respect to the IBS group, based on conflicting data from
the available studies [21-23], it remains difficult to deter-
mine whether depression and/or anxiety predict worse
clinical outcomes. The present study, in contrast to previ-
ous investigations, suggests that there is no relationship,
either positive or negative, between both anxiety and
depression and clinical outcomes after 12 months in
patients with IBS. However, the present study did not
achieve the estimated sample size in either the HCV or IBS
group leaving us with insufficient power to be secure in
determining whether such a relationship really exists.
Thus findings of this study should be interpreted with cau-
tion, especially with respect to the IBS and HCV groups.
Moreover, the three groups were not homogenous at base-
line and in future studies it may be better if of all patients
were either in remission or in relapse at baseline. Due to
the limitations of our study, and the continuing uncer-
tainty from the published literature, longer and larger pro-
spective studies are needed to better understand the
relationship between psychological variables and relapse
of somatic symptoms in these patients.
The largest limitation of this study may be too short a time
frame. It is a difficult issue, as patients with all three stud-
ied conditions relapse less frequently than once a year. In
fact, over 5 years, 25% of HCV patients will clear the virus
[39] and the rest will still be carriers. Similarly in IBS, in a
two-year period, 2–18% of patients have worse symp-
toms, 30–50% have unchanged symptoms and in the
remainder symptoms either disappear or significantly
improve [23]. In IBD, in a 2-year period approximately
30% of patients relapse [40]. This fact may explain why
patients with inactive disease at baseline were at lower risk
of active disease at 12 months. Thus, prospective investi-
gations should probably last at least five years to accu-
rately observe the relationship between psychological
status and clinical outcomes in these particular patient
groups.
Moreover, the definition of remission/relapse and a
method of its measurement necessarily varied in these
three diseases. In HCV for example, remission was defined
as a clearance of the virus as measured by the blood test.
In IBS, there are no precise disease activity indices availa-
ble and thus, in this study subjective standardised ques-
tions on patients' perception of symptoms were chosen to
evaluate the remission/relapse status. Finally, in both sub-
types of IBD, disease activity indices are in the form of
questionnaires which have been previously validated and
widely used. One can, thus, argue that comparisons of
these three disorders in terms of their disease activity are
not fully justified due to these methodological differencesPage 7 of 9
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ever, we would argue that these are the relevant outcomes
to compare as these measures address the clinically rele-
vant outcomes which both doctors and patients with
these diseases seek.
Thus, despite its limitations, this study clearly showed that
there is a need for more research exploring a link between
psychological status and clinical outcomes. In light of the
findings of the current study, longer lasting studies with
larger and more homogenous groups of patients are
clearly warranted.
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